Abstract
Pegylated interferon alfa (PegIFNα) has limited efficacy in the treatment of chronic hepatitis B (CHB). Although many biomarkers related to hepatitis B virus (HBV) have been proposed to stratify patients, the response rate to PegIFNα is still unsatisfactory. Herein, our data suggest that the single-nucleotide polymorphism (SNP) rs10838543 in TRIM22 potentiates a positive clinical response to PegIFNα treatment in patients with hepatitis B e antigen-positive CHB by increasing the levels of IFNL1, CCL3, and CCL5. These observations can help guide treatment decisions for patients with CHB to improve the response rate to PegIFNα.
Keywords:
chronic hepatitis B; pegylated interferon alfa; single-nucleotide polymorphism; tripartite motif-containing 22.
MeSH terms
-
Antiviral Agents* / therapeutic use
-
DNA, Viral
-
Hepatitis B, Chronic* / drug therapy
-
Hepatitis B, Chronic* / genetics
-
Humans
-
Interferon-alpha* / genetics
-
Interferon-alpha* / pharmacology
-
Minor Histocompatibility Antigens / genetics
-
Minor Histocompatibility Antigens / therapeutic use
-
Polymorphism, Single Nucleotide
-
Receptors, Cytokine / genetics
-
Receptors, Cytokine / therapeutic use
-
Recombinant Proteins / genetics
-
Recombinant Proteins / therapeutic use
-
Repressor Proteins / genetics
-
Signal Transduction
-
Treatment Outcome
-
Tripartite Motif Proteins* / genetics
-
Tripartite Motif Proteins* / metabolism
Substances
-
Antiviral Agents
-
DNA, Viral
-
Interferon-alpha
-
Minor Histocompatibility Antigens
-
Receptors, Cytokine
-
Recombinant Proteins
-
Repressor Proteins
-
TRIM22 protein, human
-
Tripartite Motif Proteins